Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model

This publication has 26 references indexed in Scilit:

• Efficacy of Gene Therapy for a Prototypical Lysosomal Storage Disease (GSD-II) Is Critically Dependent on Vector Dose, Transgene Promoter, and the Tissues Targeted for Vector Transduction
  Molecular Therapy, 2002
• Acid a-Glucosidase Deficiency (Glycogenosis Type II, Pompe Disease)
  Current Molecular Medicine, 2002
• Long-Term Efficacy after [E1^-, polymerase^-] Adenovirus-Mediated Transfer of Human Acid-α-Glucosidase Gene into Glycogen Storage Disease Type II Knockout Mice
  Human Gene Therapy, 2001
• Recombinant human α-glucosidase from rabbit milk in Pompe patients
  The Lancet, 2000
• Towards a molecular therapy for glycogen storage disease type II (Pompe disease)
  Molecular Medicine Today, 2000
• Human Acid -Glucosidase from Rabbit Milk Has Therapeutic Effect in Mice with Glycogen Storage Disease Type II
  Human Molecular Genetics, 1999
• Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-α-glucosidase
  Proceedings of the National Academy of Sciences, 1999
• High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease.
  Proceedings of the National Academy of Sciences, 1996
• Glycogenosis type II (acid maltase deficiency)
  Muscle & Nerve, 1995
• Characterization of the human lysosomal α-glucosidase gene
  Biochemical Journal, 1990